Business Context and Reporting Period
This Form 6-K filing by Immatics N.V. was submitted on November 8, 2024. The report details updated clinical data for the company's lead TCR-T cell therapy candidates, IMA203 and IMA203CD8, as well as preclinical data for next-generation cell therapies. The filing focuses on scientific and clinical progress rather than financial performance.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current report on clinical developments and does not contain financial statements or financial metrics.
Material Changes and Clinical Data Updates
IMA203 (Phase 1b Dose Expansion)
Data cutoff: August 23, 2024. The update includes all 41 infused patients in the Phase 1b dose expansion, comprising 28 melanoma patients and 13 non-melanoma patients. Key efficacy metrics include:
- Cutaneous Melanoma (N=13): Confirmed Objective Response Rate (cORR) of 54%; Tumor Shrinkage in 85% of patients; Disease Control Rate (DCR) at week 6 of 92%.
- Uveal Melanoma (N=10): cORR of 60%; Tumor Shrinkage in 100% of patients; DCR at week 6 of 90%.
- Other Indications: Responses observed in ovarian cancer, synovial sarcoma, and other solid tumors.
IMA203CD8 (Phase 1 Dose Escalation)
Data cutoff: September 30, 2024. The trial included 44 heavily pretreated patients with solid tumors. Key findings include:
- Efficacy: Objective Response Rate (ORR) of 41% (17/41 patients); Confirmed ORR of 41% (14/34 patients). Tumor shrinkage observed in 84% of patients. Median Duration of Response (mDOR) was 9.2 months.
- Safety: Most frequent adverse events were expected cytopenias and cytokine release syndrome (CRS). One Grade 5 adverse event (fatal sepsis) was reported. Two patients experienced dose-limiting toxicities at dose level 4b, leading to a dosing adjustment to level 4a.
- Dosing: The Maximum Tolerated Dose (MTD) has not yet been determined. Dose escalation beyond level 4a has been reinitiated following protocol modifications.
Preclinical Data and New Approaches
The company presented preclinical data on:
- mbIL15 Armoring: Evaluation of TCR-T cells armored with membrane-bound IL-15 to enhance durability and activity in tumors with low PRAME copy numbers.
- Allogeneic Therapy (ACTallo): Development of an off-the-shelf cell therapy approach.
- Combination with mRNA Vaccine: Data on combining IMA203 with a Moderna PRAME-encoding mRNA vaccine showed T cell activation, cytokine secretion, and proliferation. A first-in-human combination study is planned for up to 15 patients.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the timing of data read-outs, clinical trial outcomes, and potential partnerships. Management anticipates that the enhanced pharmacology of IMA203CD8 may address hard-to-treat solid tumors with medium-level PRAME copy numbers. Risks include the preliminary nature of the data, uncertainties in clinical trial outcomes, and the possibility that actual results may differ materially from expectations due to factors beyond management's control.
Investor Verification Checklist
- Verify the safety profile and MTD determination timeline for IMA203CD8 following the dose-limiting toxicities at level 4b.
- Confirm the durability of responses in the IMA203CD8 cohort, specifically the 10 ongoing responses as of the data cutoff.
- Monitor the initiation and design of the planned first-in-human combination study of IMA203 with the PRAME mRNA vaccine.
- Review the company's cash position and burn rate in subsequent filings, as this 6-K does not provide financial liquidity data.
- Assess the feasibility of the allogeneic ACTallo platform and its potential impact on commercial scalability.